By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


First Look: Stryker Acquisition of K2M

Stryker’s $1.4 billion acquisition of spinal device company K2M Group is expected to clear Hart-Scott-Rodino without concerns, antitrust attorneys familiar with the space told CTFN.featured

Fresenius Has Not Certified Compliance for NxStage Medical Acquisition

CTFN confirmed with a source close to the deal that Fresenius has not certified substantial compliance with the U.S. Federal Trade Commission’s second request, as some marketfeatured

Spectranetics Nearing Expected FDA Approval of Stellarex

Spectranetics Corp. is expected to receive Food and Drug Administration approval this summer for its drug-coated balloon catheter used to treat peripheral artery disease (PAD), makingfeatured

Court Order Could Tip Delaware Case in Abbott’s Favor

Last Friday’s ruling by a federal court in Washington, D.C., against Alere’s Arriva Medical subsidiary could help persuade the Delaware Chancery Court to allow Abbott Laboratoriesfeatured

Judge to Rule by End of Month on Alere’s Arriva Medical Unit

A federal judge said this afternoon that he will decide by the end of the month whether to restore Arriva Medical’s Medicare billing rights while an administrative law judge determinesfeatured

Alere Races Against Trial Date to Complete Arriva Medical Appeal

Alere is hoping to erase one major obstacle to its merger with Abbott Laboratories — the uncertainty over its Arriva Medical subsidiary — before an April court date that will determine thefeatured

Corrected: Judge Promises to Protect Alere from Impending Drop-Dead Date

Revised at 1:56pm EST – The Delaware Chancery Court has set aside six days at the end of April for a trial to determine whether Abbott Laboratories can walk away from its acquisition of Alere, which would brush upfeatured

Judge Plans April Trial Over Alere/Abbott Break-Up

A Delaware judge rejected pleas by Alere Inc. to schedule a fast trial over the company’s efforts to salvage its $5.8 billion acquisition by Abbott Laboratories, siding instead with Abbott’s request for an April court date. Alere had asked the court for an expedited trial beginningfeatured

Abbott Builds Case Against Alere Merger

Alere Inc., which is fighting to save its merger with Abbott Laboratories, agreed Tuesday to share more information about the variety of investigations into its practices being conducted by federal agencies. The agreement comes as Abbott continues to unveil information about the investigations through a suit filed November 4, askingfeatured

Abbott Says Suit Not Aimed at Breaking Alere Deal

Abbott Laboratories said a new suit seeking confidential legal and regulatory information from Alere is not an attempt to break the companies’ $5.4 billion merger, even as the companies accelerate toward a January court date that could do just that. “The objective of the (new) lawsuit is to obtain important information before the transaction is … Read Morefeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.